Indivior reports Q2 non-GAAP EPS 51c, consensus 25c

Reports Q2 revenue $302M, consensus $241.67M. “Sublocade net revenue and pricing stability in Suboxone Film in the U.S. drove solid results in Q2, leading us to raise our 2025 financial guidance,” said CEO Joe Ciaffoni. “In the second half of 2025, we are focused on implementing Phase 1 of the Indivior (INDV) Action Agenda, Generate Momentum, which includes growing U.S. SUBLOCADE net revenue and simplifying the organization to generate operational momentum. We are committed to achieving our financial guidance for the year, investing in U.S. SUBLOCADE growth and implementing organizational changes that will strongly position us to advance to Phase 2 of the Indivior Action Agenda, Accelerate, at the start of 2026 and immediately realize bottom line accretion.” “We are increasing our 2025 financial guidance to reflect better-than-expected net revenue performance in the first half of the year,” said CFO Ryan Preblick. “Our expectations for total net revenue and adjusted EBITDA are increasing by $65M and $48M, respectively, at the mid-points from our original guidance.”